SOLUBLE MEDIATOR Russian patent published in 2018 - IPC A61K38/10 A61P3/10 G01N33/48 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: group of inventions relates to medicine and relates to a pharmaceutical composition for the treatment or prevention of a disease or condition mediated by effector T cell function, inflammation or sepsis comprising any one or more of the following: i) soluble CD52 glycoprotein comprising an amino acid sequence that is at least 95% identical to the amino acid sequence GQNDTSQTSSPS (SEQ ID NO: 3), and carbohydrate, ii) a fusion protein comprising soluble CD52 glycoprotein as a first protein, and a second protein; iii) a polynucleotide encoding the peptide portion of soluble CD52 glycoprotein of part i) or the fusion protein of part ii); iv) a vector comprising the polynucleotide of part iii); v) an isolated cell comprising the polynucleotide of part iii) or the vector of part iv); and a pharmaceutically acceptable carrier. Group of inventions also relates to a method of treating or preventing a disease or condition mediated by effector T cell function, inflammation or sepsis in a subject, comprising administering to the subject a therapeutically effective amount of said composition; a method for diagnosing the subject's sensitivity to developing a disease or condition mediated by effector T-cell function, inflammation, or sepsis.

EFFECT: group of inventions provides suppression of effector T-cell function.

23 cl, 21 ex, 29 dwg, 1 tbl